Intraperitoneal chemotherapy for women with epithelial ovarian cancer

Oncologist

Volumn 13, Issue 4, 2008, Pages 403-409

  Trimble, Edward L ^a,b   Thompson, Sharon ^b   Christian, Michaele C ^a   Minasian, Lori ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; FATIGUE; FEVER; GRANULOCYTOPENIA; HAZARD RATIO; HEARING LOSS; HUMAN; LEUKOPENIA; NAUSEA AND VOMITING; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATIENT SELECTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 43549085283     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0058     Document Type: Review

References (26)

1. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
2. National Cancer Institute. Ovarian Cancer: Treatment. Available at http://www.cancer.gov/cancertopics/treatment/ovarian. Accessed December 13, 2007.
3. Dedrick R, Myers C, Bungay PM et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
4. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13:219-242.
5. McClay EF, Howell SB. A review: Intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol 1990;36:1-6.
6. Markman M, Francis P, Rowinsky E et al. Intraperitoneal paclitaxel: A possible role in the management of ovarian cancer? Semin Oncol 1995;22(suppl 6):84-87.
7. Howell SB, Pfeifle CL, Wung WE et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-851.
8. Kirmani S, Braly PS, McClay EF et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994;54:338-344.
9. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
10. Polyzos A, Tsavaris N, Kosmas C et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291-296.
11. Gadducci A, Carnino F, Chiara S et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000;76:157-162.
12. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
13. Yen MS, Juang CM, Lai CR et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:55-60.
14. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
15. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003;13(suppl 2):196-203.
16. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006;(1):CD005340.
17. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst 2006;98:1655-1663.
18. Hess LM, Benham-Hutchins M, Herzog TJ et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007;17:561-570.
19. Wenzel LB, Huang HQ, Armstrong DK et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:437-443.
20. National Cancer Institute. NCI Clinical Announcement: Intraperitoneal Chemotherapy for Ovarian Cancer, January 5, 2006. Available at http://ctep.cancer.gov/highlights/clin_annc_010506.pdf. Accessed January 21, 2008.
21. Gynecologic Oncology Group. IP Chemotherapy: Education Materials. Available at http://www.gog.org/ipchemoed/ipchemoed.html. Accessed December 13, 2007.
22. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 2006;24:988-994.
23. Fujiwara K, Armstrong D, Morgan M et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007;17:1-20.
24. Elit L, Oliver TK, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: A systematic review with metaanalyses. Cancer 2007;109:692-702.
25. The Johns Hopkins Ovarian Cancer Center of Excellence. Hot Topics in Ovarian Cancer. Available at http://www.ovariancancercenter.org/features/topics. cfm. Accessed December 13, 2007.
26. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-5171.